Journal
DIGESTIVE AND LIVER DISEASE
Volume 40, Issue -, Pages S225-S228Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1590-8658(08)60530-7
Keywords
Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis
Categories
Funding
- Italian Ministry of Health [72]
Ask authors/readers for more resources
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD. (c) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
